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New York, New York
Percutaneous coronary intervention (PCI) using balloon
angioplasty with stenting has become a mainstay in the
treatment of patients with coronary artery disease (CAD).
Over one million PCI procedures were performed in the
U.S. alone in 2000, nearly one-half of which involved
placement of a coronary stent (1). This number is expected
to increase as more revascularization procedures that were
previously thought to be surgical are now approached with
angioplasty and stents.
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Although many of the initial limitations of PCI have
been overcome by improvements in equipment and anti-
platelet therapies, restenosis continues to be a major prob-
lem. Although restenosis rates have been significantly re-
duced with the use of stents (2,3), even when stents are
used, restenosis rates in excess of 50% can be observed (4).
In addition, progression of disease in untreated vessel
segments remains an important problem for patients with
CAD following any type of revascularization, occurring at
rates approaching 7% per year (5).
In the Lescol Intervention Prevention Study (LIPS), the
overall rate of major adverse cardiac events (MACE),
defined as death, nonfatal myocardial infarction (MI), or
re-intervention, was 6% per year over 3.9 years of
follow-up in patients undergoing a first PCI (6). Although
treatment with aggressive cholesterol-lowering therapy sig-
nificantly reduced the MACE rate, the combined incidence
of cardiac death and nonfatal MI in the treated cohort was
still 1.3% per year in this population with a relatively early
stage of CAD. A comparison of the 1997 to 1998 Dynamic
Registry and the 1985 to 1986 National Heart, Lung, and
Blood Institute Registry of patients undergoing an initial
PCI procedure revealed that one-year crude mortality was
actually higher among patients in the more recent study
(5.4%) than in the earlier registry (3.6%), particularly among
women (8%), despite higher procedural success rates and
lower rates of coronary artery bypass grafting (CABG) (7).
Only after adjusting for baseline differences (i.e., age 65
years, history of diabetes or congestive heart failure [CHF],
circumstances of the procedure, and more revascularization
procedures involving totally occluded vessels and vein grafts)
were mortality rates for the two registry cohorts comparable
and the risk for the combined end point of death or MI less
for the Dynamic Registry cohort. However, the reality of
contemporary interventional practice is that patients having
the very characteristics necessitating this adjustment com-
prise an increasing percentage of the population undergoing
PCI. The average patient now undergoing PCI is at a
higher risk for cardiovascular events following the interven-
tion than were patients treated with PCI in the past (7).
Although the presence or absence of chest pain can serve
as a basic form of risk stratification among patients who
have undergone revascularization, chest pain has repeatedly
been found to have low sensitivity for the detection of
restenosis and myocardial ischemia following PCI (3,8–13).
Indeed, silent ischemia has been found to occur in nearly
60% of patients following percutaneous transluminal coro-
nary angioplasty (PTCA) (9) and in a similar number of
patients (58%) after stenting (3). Importantly, the presence
of chest pain prior to PCI does not correlate with the
recurrence of symptoms due to restenosis (3,10,13), nor
does the presence of chest pain after PCI correlate with the
presence of restenosis (8,14).
It has been well established that silent myocardial isch-
emia is associated with poorer outcomes in patients who
have not undergone PCI. In the Asymptomatic Cardiac
Ischemia Pilot (ACIP) study, both mortality (4%) and the
combination of death or MI (9%) at one year were signif-
icantly greater among patients assigned to angina-guided
medical therapy than among patients assigned to a revascu-
larization strategy (0% and 3%, respectively), despite the fact
that 23% of patients in the medically treated arm underwent
nonprotocol revascularization (15). There is no “a priori”
reason to believe that silent ischemia is less ominous in
patients who have undergone PCI. However, the use of
noninvasive testing and directed re-intervention following
PCI have never been systematically investigated.
Pfisterer et al. (12) followed 109 patients with angio-
graphically documented restenosis who had evidence of
ischemia on planar thallium-201 imaging performed six
months following PTCA; ischemia was silent in 61%. After
two years, the event rate was significantly greater in patients
with silent ischemia who did not undergo re-intervention
(17%) than in patients without ischemia (8%). Cottin et al.
(14) prospectively studied 152 patients who underwent
coronary stent placement and myocardial perfusion single-
photon emission computed tomography (SPECT) five
months later. After 40 months of follow-up, the rates of
cardiovascular death and MI were significantly lower among
patients without (1% and 2%, respectively) versus with (15%
for both) ischemia, based on stress myocardial perfusion
imaging (MPI). Importantly, 60% of patients with ischemia
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were asymptomatic. Angina was not an independent pre-
dictor of cardiovascular death or MI.
The study reported by Zellweger et al. (16) in this issue of
the Journal is an important one which further extends the
earlier observations from this group and helps define the
true incidence of silent ischemia in patients undergoing
PCI, as well as the role of MPI in defining ischemia. This
study summarizes the follow-up of 307 patients who un-
derwent stress MPI six months after stenting for a mini-
mum of 3.2 years to ascertain the incidence of silent versus
symptomatic ischemia after stenting, predictors of silent
versus symptomatic ischemia, predictors of long-term out-
come vis a vis symptomatic status, and the incremental
value of stress MPI over clinical and stress testing variables.
They also present follow-up data for an additional 17
patients who underwent re-intervention as a result of the
six-month stress MPI study, as well as for 32 patients with
evidence of ischemia in untreated territories on the six-
month MPI study.
Six months after PCI, 32% of patients had evidence of
myocardial ischemia by stress MPI. Ischemia was located in
the target vessel territory in 72% of these patients and in a
remote territory in 28%. Of 68 patients with chest pain six
months after stenting, 37% had no evidence of ischemia by
stress MPI. Conversely, of 81 patients with target vessel
ischemia documented by MPI, only 38% had angina. Thus,
ischemia was silent in 62% of patients with target vessel
ischemia six months after PCI; 66% of these patients had
angina before stenting. Of the 32 patients with ischemia in
an untreated territory, 59% had silent ischemia. Patients
with silent target vessel ischemia had fewer CAD risk
factors, were less likely to have hypertension or previous
CABG, had less severely stenotic lesions treated, less often
had ischemic stress electrocardiographic (ECG) changes,
more often had peri-infarct ischemia, and had less severe
and less extensive ischemia on their stress MPI. Thus, their
summed stress scores (SSS) and summed difference scores
(SDS) were lower.
After a mean follow-up of 4.1 years, the overall rate of the
composite end point (all-cause mortality, nonfatal MI, and
“late” revascularization) was 22%, whereas the rate of death
and nonfatal MI was 8%, or 2% per year. The composite
event rate was significantly greater for the 65 patients with
target vessel ischemia who did not undergo re-intervention
(38%) than for the 242 patients without ischemia (17%),
although this difference was primarily driven by repeat
revascularization. Event rates for both patients with silent
ischemia and for those with symptomatic ischemia were
significantly greater than for patients with no ischemia. The
best predictors of an adverse outcome were diabetes and
extent of ischemia. Although patients with silent target
vessel ischemia had less severe and less extensive ischemia,
there was no significant difference in outcome between
patients with silent and symptomatic ischemia, although
there was a trend toward a better outcome for patients in
whom ischemia was silent.
The authors also demonstrate the incremental prognostic
value of stress ECG over clinical information and of stress
MPI over clinical plus stress ECG data. Of the 356 patients
in the initial “diagnostic group,” only 19% had angina six
months after stent implantation, 13% had nondiagnostic
ECG changes during stress, 13% had ischemic ECG
changes, and 32% had scan evidence of ischemia. This
reaffirms the findings of previous investigations that showed
poor accuracy of chest pain and stress ECG changes for the
detection of restenosis and ischemia or for the prediction of
the occurrence of adverse cardiac events (8,10,12–14,17).
The accuracy of stress MPI for the detection of restenosis
has been found to range from 79% to 89% when performed
six or more months after PCI with or without stenting
(10,17,18). The incidence of asymptomatic restenosis fol-
lowing coronary stenting has been found to range from 30%
to 58% in studies using angiography (2,3). Thus, the
percentages of patients with silent ischemia reported in the
study by Zellweger et al. (16)—62% for those with target
vessel ischemia and 59% for those with ischemia in an
untreated territory—are slightly above the rates found using
invasive methods. This would suggest that the definition
used by Zellweger et al. (16) to define ischemia (i.e., SDS
1) is perhaps overly sensitive. Although it may not seem
surprising that, in the present study, patients with silent
ischemia had less severe and extensive perfusion defects, and
that SDS 4 best separated patients with silent from those
with symptomatic ischemia, others have shown that the
extent and severity of ischemia are similar in patients with
silent and symptomatic ischemia (10,13). Although a low
SDS was the most powerful predictor of silent ischemia, the
absence of hypertension and greater lesion severity at the
time of PCI were also associated with silent ischemia, in
agreement with earlier studies (11,19). Importantly, the
current investigation also demonstrates that the incidence of
silent ischemia is the same in patients with and those
without diabetes, in agreement with previous studies
(3,11,13).
Zellweger et al. (16) show that defect severity on MPI,
not symptomatic status, is the most powerful predictor of
adverse events, and that differences in event rates are seen
among patients with no ischemia, those with mild ischemia,
and those with moderate to severe ischemia. Cottin et al.
(14) similarly demonstrated that stress MPI, and not symp-
tom status, best predicted outcome following coronary
stenting. The important point made by this study is that,
although there was a trend toward better outcomes for
patients with silent ischemia, who tended to have less
extensive and severe ischemia compared with patients with
symptoms, there was no significant difference in outcomes
between the two groups, both of which faired worse than
patients with no ischemia. Thus, although asymptomatic
patients as a group may be less likely to have an adverse
event following PCI, the only way to ascertain any particular
patient’s risk with certainty is to perform stress MPI. On the
other hand, because a significant number of patients with
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symptoms had no evidence of ischemia on stress MPI, it
could be argued that the only way to accurately ascertain the
risk for any particular patient with chest pain following PCI
is to perform perfusion imaging. However, an important
point to learn from this study is that the event rate for the
group of patients with chest pain who did not have ischemia
on stress MPI was similar to that of patients with silent
ischemia. As no details regarding the former group are
provided, it is unclear whether stress MPI in these patients
was false negative, what types of events befell them, or
whether re-interventions performed were largely symptom-
driven.
Important information can also be derived by assessing
the outcome of the 49 patients who were excluded from the
“prognostic patient” group. Seventeen patients underwent
re-intervention at the time of six-month stress MPI; 16
patients had target vessel ischemia and 35% were asymp-
tomatic. The overall event rate in this cohort was 18%, less
than that of the cohort with target vessel ischemia who did
not undergo stress MPI-driven re-intervention, but similar
to that of the nonischemic cohort. Thirty-two patients had
ischemia in a nonrevascularized territory at the time of the
six-month stress MPI. The MACE rate in this cohort,
driven primarily by revascularization procedures, was 25%,
or 7% per year, whereas the death rate was 3%.
The major finding of the present study is that silent
ischemia occurs frequently after coronary stenting, both as a
result of restenosis and disease progression in untreated
vascular territories. Patients with ischemia have a worse
prognosis than those with normal perfusion, whether isch-
emia is silent or symptomatic. The long-term outcome is
most closely associated with the extent and severity of
myocardial ischemia, which can be accurately assessed by
stress MPI. Stress MPI adds incremental prognostic infor-
mation to clinical and stress ECG data in post-PCI pa-
tients. There is also suggestive evidence that directed
re-intervention, based on stress MPI, can further improve
the outcome of patients.
One obvious limitation of this study is the absence of
angiographic follow-up. Although highly accurate, stress
MPI is neither 100% sensitive nor 100% specific. Given the
higher incidence of silent ischemia reported in the current
study compared with angiographic studies, it is possible that
some patients purported to have silent ischemia actually had
a false-positive stress MPI. This would lead to an overesti-
mation of the rate of silent ischemia and an underestimation
of the adverse event rate among patients who truly have
silent ischemia, by including patients without restenosis. A
further limitation of the study is the small number of
adverse events in the study cohort, other than re-
interventions. Although this is one of the larger studies to
examine the outcome of patients with silent ischemia
following PCI, because of the low incidence of cardiovas-
cular death and MI in the “prognostic group” (2% per year),
the study lacks sufficient power to detect a difference in the
occurrence of these important end points. A final limitation
of the present study is that patients who underwent re-
intervention as a result of the six-month stress MPI were
excluded from subsequent analyses. Important information
on the impact of stress MPI-driven re-intervention on
patient outcome might arise from such an analysis.
This study reconfirms the importance of silent ischemia
in post-PCI patients, as well as the likely benefits of directed
re-intervention in improving the long-term outcome of this
growing patient population. It seems reasonable to suggest
that stress MPI, performed six months after PCI, can
identify a significant number of patients who are at risk of
future cardiac events and who warrant further invasive
evaluation and therapy.
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